Medical Innovation

Reimbursement “Furies” Real, But Won’t Avenge Pharma Til 2017, Says Citi

Posted by on Dec 4, 2012 in Adherence, Company, Cost/Comparative Effectiveness, Diagnostics, Health Technology Assessments, Medical Innovation, Payer Management Tool, Payers: Commercial, Payers: Managed Medicaid/Medicare, Payment Reform, Pharmaceuticals, Pricing

“Beware the Three Furies,” warns Citi analyst Andrew Baum.  In a report for pharma investors published Nov. 29., Baum turns to classical mythology to describe shared savings models, drug pathways...

Learn More

Sanofi Blinks First: Zaltrap Price Cut Proves HTA Has Reached The US

Posted by on Nov 12, 2012 in Company, Cost/Comparative Effectiveness, Health Technology Assessments, Medical Innovation, Payer Management Tool, Payers: Commercial, Payers: Managed Medicaid/Medicare, Payment Reform, Pharmaceuticals, Pricing, Product Launch, Value-based pricing

Sanofi’s decision last week to cut the price of its colon cancer drug Zaltrap by up to 50% showed that the US market is no longer immune to European-style drug price pressure. Never mind that the move...

Learn More

Actelion’s Opsumit Will Test Whether Outcomes Data Can Replace Head-to-Head

Posted by on Nov 2, 2012 in Company, Cost/Comparative Effectiveness, Health Technology Assessments, Medical Innovation, Payers: Commercial, Payers: Managed Medicaid/Medicare, Pharmaceuticals, Pricing, Product Launch

Actelion pulled out all the stops in designing the Phase III trial of its pulmonary arterial hypertension drug Opsumit (macitentan), filed at FDA on Oct 22.  And no wonder: the biotech’s future depends on it,...

Learn More

The Value Debate: Can Personalized Drugs Support Personalized Pricing?

Posted by on Oct 10, 2012 in Adherence, Company, Cost/Comparative Effectiveness, Health Technology Assessments, Medical Innovation, Payers: Commercial, Payment Reform, Personalized Medicine, Pharmaceuticals, Pricing, Value-based pricing

“Personalized health care requires a new reimbursement model,” declared Roche’s VP Global Pricing & Market Access Jens Grueger in the elegant London county hall debating chamber on...

Learn More

Risk-Shares Pop Up Again As Payers, Pharma Circle New Payment Models

Posted by on Oct 3, 2012 in Company, Cost/Comparative Effectiveness, Health Technology Assessments, Medical Innovation, Payer Management Tool, Payers: Commercial, Payment Reform, Pharmaceuticals, Physician practice patterns, Pricing, Product Launch, Value-based pricing

Say you’re GSK, and a head-to-head trial pitting your drug against the market leader showed non-inferiority. Say, too, that even though you assembled some trial evidence that patients preferred your drug vs....

Learn More